首页> 中文期刊> 《生物医学研究杂志:英文版》 >RNA-seq analysis identified hormone-related genes associated with prognosis of triple negative breast cancer

RNA-seq analysis identified hormone-related genes associated with prognosis of triple negative breast cancer

         

摘要

Triple negative breast cancer(TNBC) is an aggressive subtype of breast cancer that currently lacks effective biomarkers and therapeutic targets required to investigate the diagnosis and treatment of TNBC. Here we performed a comprehensive differential analysis of 165 TNBC samples by integrating RNA-seq data of breast tumor tissues and adjacent normal tissues from both our cohort and The Cancer Genome Atlas(TCGA). Pathway enrichment analysis was conducted to evaluate the biological function of TNBC-specific expressed genes. Further multivariate Cox proportional hazard regression was performed to evaluate the effect of these genes on TNBC prognosis. In this report, we identified a total of 148 TNBC-specific expressed genes that were primarily enriched in mammary gland morphogenesis and hormone levels related pathways, suggesting that mammary gland morphogenesis might play a unique role in TNBC patients differing from other breast cancer types. Further survival analysis revealed that nine genes(FSIP1, ADCY5, FSD1, HMSD, CMTM5, AFF3, CYP2 A7, ATP1 A2,and C11 orf86) were significantly associated with the prognosis of TNBC patients, while three of them(ADCY5,CYP2 A7, and ATP1 A2) were involved in the hormone-related pathways. These findings indicated the vital role of the hormone-related genes in TNBC tumorigenesis and may provide some independent prognostic markers as well as novel therapeutic targets for TNBC.

著录项

  • 来源
    《生物医学研究杂志:英文版》 |2020年第2期|P.129-138|共10页
  • 作者单位

    Department of Breast Surgery Women''s Hospital of Nanjing Medical University Nanjing Maternity and Child Health Care Hospital Nanjing Jiangsu 210004 ChinaDepartment of Epidemiology Center for Global Health School of Public Health Nanjing Medical University Nanjing Jiangsu 211116 ChinaJiangsu Key Lab of Cancer Biomarkers Prevention and Treatment Collaborative Innovation Center for Cancer Medicine Nanjing Medical University Nanjing Jiangsu 211116 China;

    Department of Epidemiology Center for Global Health School of Public Health Nanjing Medical University Nanjing Jiangsu 211116 ChinaJiangsu Key Lab of Cancer Biomarkers Prevention and Treatment Collaborative Innovation Center for Cancer Medicine Nanjing Medical University Nanjing Jiangsu 211116 China;

    Department of Epidemiology Center for Global Health School of Public Health Nanjing Medical University Nanjing Jiangsu 211116 ChinaJiangsu Key Lab of Cancer Biomarkers Prevention and Treatment Collaborative Innovation Center for Cancer Medicine Nanjing Medical University Nanjing Jiangsu 211116 China;

    Department of Breast Surgery Women''s Hospital of Nanjing Medical University Nanjing Maternity and Child Health Care Hospital Nanjing Jiangsu 210004 China;

    Department of Epidemiology Center for Global Health School of Public Health Nanjing Medical University Nanjing Jiangsu 211116 ChinaJiangsu Key Lab of Cancer Biomarkers Prevention and Treatment Collaborative Innovation Center for Cancer Medicine Nanjing Medical University Nanjing Jiangsu 211116 China;

    Department of Epidemiology Center for Global Health School of Public Health Nanjing Medical University Nanjing Jiangsu 211116 ChinaJiangsu Key Lab of Cancer Biomarkers Prevention and Treatment Collaborative Innovation Center for Cancer Medicine Nanjing Medical University Nanjing Jiangsu 211116 ChinaDepartment of Bioinformatics School of Biomedical Engineering and Informatics Nanjing Medical University Nanjing Jiangsu 211116 China;

    Department of Clinical Management National Center for STD Control Institute of Dermatology Chinese Academy of Medical Sciences Nanjing Jiangsu 210042 China;

    Department of Epidemiology Center for Global Health School of Public Health Nanjing Medical University Nanjing Jiangsu 211116 ChinaJiangsu Key Lab of Cancer Biomarkers Prevention and Treatment Collaborative Innovation Center for Cancer Medicine Nanjing Medical University Nanjing Jiangsu 211116 China;

    Department of Epidemiology Center for Global Health School of Public Health Nanjing Medical University Nanjing Jiangsu 211116 ChinaJiangsu Key Lab of Cancer Biomarkers Prevention and Treatment Collaborative Innovation Center for Cancer Medicine Nanjing Medical University Nanjing Jiangsu 211116 China;

    Department of Epidemiology Center for Global Health School of Public Health Nanjing Medical University Nanjing Jiangsu 211116 ChinaJiangsu Key Lab of Cancer Biomarkers Prevention and Treatment Collaborative Innovation Center for Cancer Medicine Nanjing Medical University Nanjing Jiangsu 211116 China;

    Department of Epidemiology Center for Global Health School of Public Health Nanjing Medical University Nanjing Jiangsu 211116 ChinaJiangsu Key Lab of Cancer Biomarkers Prevention and Treatment Collaborative Innovation Center for Cancer Medicine Nanjing Medical University Nanjing Jiangsu 211116 China;

    Department of Breast Surgery Women''s Hospital of Nanjing Medical University Nanjing Maternity and Child Health Care Hospital Nanjing Jiangsu 210004 China;

    Department of Epidemiology Center for Global Health School of Public Health Nanjing Medical University Nanjing Jiangsu 211116 ChinaJiangsu Key Lab of Cancer Biomarkers Prevention and Treatment Collaborative Innovation Center for Cancer Medicine Nanjing Medical University Nanjing Jiangsu 211116 China;

  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 肿瘤学;
  • 关键词

    RNA-seq; triple negative breast cancer; prognosis; differential expression;

    机译:RNA-SEQ;三重阴性乳腺癌;预后;差异表达;
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号